New device aims to sharpen liver tumor ablation

NCT ID NCT05582018

Terminated Knowledge-focused Sponsor: Techsomed Medical Technologies LTD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This pilot study tested a device called BioTraceIO 360, designed to help doctors plan and monitor procedures that destroy liver tumors using heat. The study planned to enroll 30 people with liver cancer, but only 4 participated before it was stopped early. Researchers looked at whether the device's suggestions matched the doctor's own plans and if any device-related side effects occurred.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BioTraceIO 360 device
What this could lead to: If successful, this device could help doctors more accurately plan and monitor liver tumor ablation procedures, potentially improving outcomes.
What could go wrong: This was a very small pilot study (only 4 participants) that was terminated early. The device may not work as intended or may not be better than standard planning methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver cancer Liver Neoplasms metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA METASTATIC LIVER CANCER

Contacts and locations

Locations

Einstein Medical Center

Philadelphia, Pennsylvania, 19141, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.